press release

September 20, 2017

– Investigational RNAi Therapeutic Patisiran Meets Primary and All Secondary Endpoints, with Highly Significant Reduction In Neuropathy Progression and Improvement in Quality of Life at 18 Months Relative to Placebo – – Alnylam Intends to File New Drug Application (NDA) in Late 2017 and Marketing Authorisation Application (MAA) in Early 2018– – Full Results to be Presented at 1st European ATTR ...

press release

June 19, 2017

- Company Appoints Chief Financial Officer and Other Key Roles Ahead of Anticipated Transition to Commercialization CAMBRIDGE, Mass. (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today the appointment of several experienced industry leaders to key leadership roles including: Manmeet S. Soni, Chief Financial Officer; Theresa Heggie, Senior ...

press release

June 19, 2017

- Advanced Industry Leading RNAi Therapeutics Pipeline with Eight Clinical Programs, Including Three Programs in Late Stage Development Maintained Strong Balance Sheet with $962 Million in Cash and Plans to End 2017 with Greater than $700 Million in Cash CAMBRIDGE, Mass. (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results ...

press release

May 5, 2017

- Company Announces Departure of Chief Business Officer and Promotion of Pushkal Garg, M.D., to Chief Medical Officer CAMBRIDGE, Mass. (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that David Alexandre "DA" Gros, M.D., Senior Vice President and Chief Business Officer, plans to leave the company for personal reasons. ...

press release

May 5, 2017

- New Phase 1 Results Demonstrate Effective Bleed Management with Replacement Factor and Bypassing Agents During Fitusiran Administration Stability Study Results Support a Greater than Two Year Product Shelf Life at Room Temperature Storage Conditions CAMBRIDGE, Mass. (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company today announced new results from ...

press release

May 5, 2017

- Results Provide Continued Evidence Supporting Potential for ALN CC5 to Reduce Dose and Frequency of Eculizumab in Patients with PNH CAMBRIDGE, Mass. (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today presented new results from Part C of its Phase 1/2 clinical trial with ALN CC5, a subcutaneously administered investigational ...

press release

May 5, 2017

CAMBRIDGE, Mass. (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming R&D Day, including a live video stream, on the Investors section of the company's website, www.alnylam.com, on the morning of December 16, 2016. Alnylam management and leading physicians will ...

press release

May 5, 2017

- Advanced Industry Leading RNAi Therapeutics Pipeline with Eight Clinical Programs, Including Three Programs in Late Stage Development; Discontinued Revusiran Development Maintained Strong Balance Sheet with $1.1 Billion in Cash and Expects to End 2017 with Greater than $700 Million in Cash CAMBRIDGE, Mass. (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported ...

press release

May 5, 2017

- Three Mid to Late Stage Programs Advancing Toward Potential Commercialization In Addition, Company Announces Positive Preliminary Results fromPhase 1 Study of ALN TTRsc02 CAMBRIDGE, Mass. (BUSINESS WIRE) Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting its R&D Day in New York City today. During the event, the Company will ...

press release

May 5, 2017

- Once Monthly, Subcutaneous Fitusiran Achieves Median Annualized Bleeding Rate (ABR) of Zero in this Hemophilia Patient Segment with Highest Unmet Need Fitusiran Generally Well Tolerated with No Thromboembolic Events, Including with Co Administration of Bypassing Agents Alnylam On Track to Initiate Phase 3 Program in Early 2017 Management to Discuss New Clinical Data in Webcast Conference Call ...